Drug Database
DI

diclofenac (Oxa Gel / diclofenac, topical)

✓ Approved

Actavis · PTGS1 · 小分子

什么是 diclofenac?

diclofenac 是一种小分子,由Actavis研发。该药已获批,用于治疗相关适应症,给药途径:Transdermal。

药物档案

商品名Oxa Gel, diclofenac, topical
公司Actavis
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Transdermal
状态Approved

作用机制

分子靶点

diclofenac 作用于 2 个分子靶点:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

diclofenac 针对 5 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersMusculoskeletal pain✓ Approved
Musculoskeletal and connective tissue disordersMyositis✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Injury, poisoning and procedural complicationsTraumatic shock✓ Approved
Skin and subcutaneous tissue disordersActinic keratosisPhase III

相关研究文献

PubMedDermatology online journal2026-11-17

Prescribing patterns for topical corticosteroids versus advanced targeted topical therapies in chronic inflammatory skin diseases: A 2022-2024 claims analysis.

Burshtein Joshua J, Vender Ronald R, Bunick Christopher C, DiRuggiero Douglas D et al.

Topical corticosteroids (TCSs) have been used since the early 1950s for treatment of inflammatory skin conditions, including atopic dermatitis (AD), psoriasis (PsO), and seborrheic dermatitis (SD). Although effective in treating these conditions, TCSs are associated with notable safety concerns. Advanced targeted topical (ATT) therapies have shown efficacy and safety in dermatologic clinical studies offering an alternative to TCSs. To evaluate real-world prescribing patterns for topical treatment of AD, PsO, and SD since the advent of ATT therapies. Patients with AD, PsO, and/or SD between January 1, 2020 and September 30, 2025 were retrospectively identified from IQVIA's PharMetrics Plus® claims database. Approximately 2.1-2.3 million patients filled AD, PsO, or SD prescriptions yearly from 2022 to 2024. At least 90% of these patients received prescriptions for TCSs, whereas no more than 3% received ATTs. Among patients filling topical therapy prescriptions, at least 96% received TCS prescriptions and no more than 3.2% received ATT prescriptions. Minimal year-to-year decreases in TCS prescriptions (≤ 0.7%) and increases in ATT prescriptions (≤ 0.6%) were seen in patients treated with topical therapies. The advent of ATT therapies has not meaningfully altered the topical treatment landscape for AD, PsO, and SD. Clinicians, payers, and health systems should continue to evaluate prescribing patterns, access barriers, and implementation and real-world evidence to better understand the ongoing role of ATTs and TCSs in clinical practice.

PMID 43040798
阅读全文 →
PubMedThe Journal of clinical and aesthetic dermatology2026-11-17

Microneedling-Assisted Delivery of Topical Adapalene vs Trichloroacetic Acid for the Treatment of Atrophic Postacne Scars: Randomized Controlled Clinical Trial.

Bendary Esraa E, Selim Heba H, Ehab Rana R, Salah Eman E

Atrophic postacne scarring is a common sequela in many patients with acne vulgaris. Microneedling, either as monotherapy or as microneedling-assisted delivery of different topicals, has been growing in use. To evaluate and compare the efficacy and safety of microneedling-assisted delivery of topical adapalene vs trichloroacetic acid (TCA) for atrophic postacne scars. This randomized controlled clinical trial included 60 patients with atrophic postacne scars divided into 3 equal groups: Group A, in which patients were treated with microneedling-assisted delivery of TCA 15%; Group B, in which patients were treated with microneedling-assisted delivery of adapalene cream, 0.1%; and finally, Group C, patients who received microneedling monotherapy. Group A had significantly superior results than Group B (P=0.006) and Group C (P<0.001). Significant difference was found between Groups B and C (P=0.032). This study had a small sample size and short-term follow-up. Microneedling-assisted delivery of either TCA, 15%, or topical adapalene, 0.1%, is more effective than microneedling alone. Furthermore, microneedling-assisted delivery of TCA, 15%, is superior to microneedling-assisted delivery of adapalene cream, 0.1%, for treating atrophic postacne scars, with greater clinical efficacy and patient satisfaction. However, microneedling-assisted delivery of topical adapalene provides a safer yet slower alternative.

PMID 43042366
阅读全文 →
PubMedBiomedical chromatography : BMC2026-11-17

Aloin-Loaded Milk-Derived Extracellular Vesicle-Enriched Preparation: Characterization, Skin Retention, and HPLC Method Validation.

Ferreira Suzana Dulcelina Fernandes SDF, Bianchi Sara Elis SE, Zimmermann Rafaela R, de Oliveira Gabriela Fusinatto GF et al.

Aloe vera (L.) Burm.f. (Asphodelaceae) is widely used in dermatological applications due to bioactive compounds such as aloin. This study aimed to develop and validate an HPLC method for aloin quantification in milk-derived extracellular vesicle (EV)-enriched preparations, receptor fluid, adhesive tape, and porcine ear skin and to investigate their potential as topical carriers. The method demonstrated specificity, linearity, low matrix effects (< 6.29%), precision (RSD < 5.62%), accuracy (90.52%-102.24%), and robustness. EVs were characterized by particle size, polydispersity index, zeta potential, morphology, and physicochemical stability. The aloin-loaded EV-enriched preparation showed a mean particle size of 145.07 nm and an encapsulation efficiency of 33.80%. In vitro skin retention studies revealed aloin deposition in the stratum corneum (1.426 ± 0.273 μg·cm-2), with no quantifiable amounts in the viable epidermis, dermis, or receptor fluid. This distribution may be advantageous for topical formulations intended to retain aloin at the skin surface while limiting its penetration into deeper tissues. The validated method enables reliable aloin quantification in the evaluated matrices. Further studies are needed to clarify the contribution of EVs to topical aloin delivery.

PMID 43041150
阅读全文 →
PubMedFrontiers in pharmacology2026-11-17

Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis.

Li Caiju C, Gao Yuying Y, Wei Lijuan L

Allergic conjunctivitis (AC) affects 15%-40% of the global population. Traditional network meta-analyses often group different formulations of olopatadine into a single node, obscuring concentration-dependent variations. This network meta-analysis evaluated the relative efficacy and safety of distinct olopatadine concentrations (0.1%, 0.2%, 0.77%) against other topical anti-allergic or anti-inflammatory agents. Registered in PROSPERO (CRD420261375330), this study systematically searched major databases up to 1 May 2026, for randomized controlled trials (RCTs) on adults with AC. Interventions evaluated olopatadine formulations (0.1% BID, 0.2% QD, 0.77% QD) as independent nodes alongside 0.05% epinastine, 0.025% ketotifen, 0.25% alcaftadine, 1.5% bepotastine, 0.2% loteprednol etabonate, or placebo. Frequentist random-effects network meta-analyses were performed. Nineteen randomized controlled trials (RCTs) encompassing 2,745 patients (5,141 eyes) were analyzed. For ocular itching (18 RCTs), 0.77% olopatadine demonstrated superior efficacy among dual-acting agents (SUCRA = 80.7%), significantly outperforming epinastine and ketotifen. For conjunctival hyperemia (17 RCTs), 0.25% alcaftadine demonstrated the highest likelihood of efficacy (SUCRA = 66.5%), whereas among olopatadine formulations, only 0.2% significantly outperformed placebo (SUCRA = 47.4%). Subgroup analyses showed that 0.77% olopatadine and 0.25% alcaftadine were particularly effective against acute itching in conjunctival allergen challenge models. Safety assessments across 11 RCTs yielded wide confidence intervals due to data sparsity, precluding definitive tolerability rankings. Although trial data predominantly reported mild adverse events, external evidence highlights key long-term safety concerns, notably intraocular pressure elevation associated with extended topical corticosteroid therapy such as 0.2% loteprednol etabonate. Topical dual-acting agents demonstrate outcome-specific efficacy variations in allergic conjunctivitis management. Olopatadine 0.77% excels in pruritus control, whereas alcaftadine 0.25% provides the highest likelihood of hyperemia resolution. Clinical management should adopt a personalized step-ladder approach: utilizing potent once-daily dual-acting agents (0.77% olopatadine or 0.25% alcaftadine) as first-line therapy for acute or seasonal exposure. Short-term topical corticosteroids (such as 0.2% loteprednol etabonate) should be strictly reserved for severe natural exposure non-responsive to dual-acting agents, with mandatory intraocular pressure monitoring, before transitioning back to dual-acting maintenance.

PMID 43042078
阅读全文 →
PubMedThe Journal of clinical and aesthetic dermatology2026-11-17

Cost-per-Responder Analysis of Delgocitinib Topical Cream vs Dupilumab Subcutaneous Injection for Moderate-to-Severe Atopic Hand Eczema in the United States.

Issa Naiem T NT, Balu Sanjeev S, Lyhne Lucas Raal LR, Sawad Aseel Bin AB et al.

Chronic hand eczema (CHE) is an inflammatory skin disease of the hands and wrists associated with substantial socioeconomic and quality-of-life burden. Atopic hand eczema (AHE) is a CHE subtype. Delgocitinib (topical pan-Janus kinase inhibitor) is approved in the United States (US) for moderate-to-severe CHE, including AHE. Dupilumab (interleukin-4 and 13 receptor α antagonist) is approved for moderate-to-severe atopic dermatitis (AD), including AHE. To evaluate the cost-per-responder (CPR) of delgocitinib vs dupilumab in adults with moderate-to-severe AHE inadequately controlled by topical corticosteroids from the perspective of a US third-party payer. Annual delgocitinib cost was estimated based on 3.2 flares per year and consumption per flare from published clinical trials. Dupilumab cost was based on a continuous regimen: 600 mg initial dose then 300 mg every 2 weeks. Response rates were obtained from a published matching-adjusted indirect comparison using delgocitinib DELTA 1 and 2 trials (all CHE subtypes) and dupilumab LIBERTY-AD-HAFT trial (hand/foot AD). Response was defined as Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) and Hand and Foot Investigator's Global Assessment (HF-IGA) score of 0/1 for CHE and AD, respectively. A 3% annual discount rate and 3-year horizon were applied. Delgocitinib showed lower CPR than dupilumab over 3 years. The 3-year CPR was $102,082 for delgocitinib vs $380,903 for dupilumab (savings: $278,821 per responder). Data directly comparing delgocitinib and dupilumab efficacy in AHE are not available. Delgocitinib topical cream had a lower predicted CPR than dupilumab for adults with moderate-to-severe AHE, yielding savings of 73% per responder.

PMID 43042203
阅读全文 →
PubMedCJC open2026-11-17

BiodEgradable soaked Amiodarone paTch use for the prevention of Atrial Fibrillation after cardiac surgery (The BEAT-AF Trial): Rationale and Design.

Lemma Massimo M, Chao Liu L, Scorsin Marcio M, Gregg Alexander C AC et al.

Postoperative atrial fibrillation (POAF) remains the most common complication following cardiac surgery and contributes substantially to patient morbidity and healthcare utilization. Although amiodarone is among the most effective pharmacologic agents for the prevention and treatment of POAF, its routine use is limited by systemic toxicity and drug interactions. Localized delivery strategies may achieve therapeutic myocardial concentrations while minimizing systemic exposure, but they have never been tested in appropriately powered trials. Experimental studies have indicated that epicardial and intrapericardial administration of amiodarone can reduce atrial vulnerability to tachyarrhythmias while maintaining low circulating drug levels. Preliminary clinical investigations have suggested a potential reduction in POAF incidence with topical amiodarone; however, studies have yielded inconsistent results, leaving uncertainty regarding clinical efficacy. The BiodEgradable soaked Amiodarone paTch use for the prevention of Atrial Fibrillation after cardiac surgery (BEAT-AF) trial is a single-centre, double-blind, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of topical amiodarone administration for the prevention of POAF following cardiac surgery. A minimum of 500 patients undergoing elective cardiac surgery through median sternotomy will be randomized in a 1:1 ratio to receive either amiodarone-soaked (150 mg/3 mL) or saline-soaked oxidized regenerated cellulose patches applied intra-operatively to the dome of the left atrium and the ostia of the right pulmonary veins immediately prior to sternal closure. The primary outcome is the occurrence of POAF within 5 days postoperatively. This trial will inform use of topical amiodarone as a strategy for POAF prevention in cardiac surgery patients. NCT06722196.

PMID 43042282
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diclofenac